Snellman Anniina, Tuisku Jouni, Koivumäki Mikko, Wahlroos Saara, Aarnio Richard, Rajander Johan, Karrasch Mira, Ekblad Laura L, Rinne Juha O
Turku PET Centre, University of Turku, Turku, Finland.
Turku PET Centre, Turku University Hospital, Turku, Finland.
Alzheimers Dement. 2024 Dec;20(12):8802-8813. doi: 10.1002/alz.14327. Epub 2024 Oct 30.
We investigated hippocampal synaptic density using synaptic vesicle 2A positron emission tomography (PET), and its association with amyloid beta (Aβ) and cognitive performance in healthy apolipoprotein E (APOE) ε4 carriers.
Synaptic density was assessed in 46 individuals (APOE ε4/ε4 n = 14; APOE ε3/ε4 n = 16; APOE ε3/ε3 n = 16) with [C]UCB-J-PET standardized uptake value ratios (SUVRs), by using the centrum semiovale as a reference region. Differences in hippocampal [C]UCB-J SUVRs were analyzed with analysis of variance (ANOVA) and linear models. Associations among [C]UCB-J SUVR, Aβ, hippocampal volume, and cognitive variables were analyzed with Spearman correlation.
Hippocampal synaptic density was different among the APOE groups (P= 0.016): APOE ε4/ε4 carriers had lower [C]UCB-J SUVRs compared to APOE ε3/ε3 (p = 0.013). Hippocampal synaptic density did not correlate with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) total score (rho = -0.052, p = 0.74), Alzheimer's Prevention Initiative Preclinical Cognitive Composite (APCC) score (rho = 0.17, p = 0.28), or [C]PiB uptake (rho = -0.10, p = 0.50).
Hippocampal synaptic loss emerges early in the AD continuum and is measurable in vivo in cognitively unimpaired high-risk individuals.
Synaptic density was studied in vivo in healthy older adults using [C]UCB-J positron emission tomography. Apolipoprotein E (APOE) ε4/ε4 carriers had lower hippocampal synaptic density compared to APOE ε3/ε3. Synaptic density was not associated with cognitive performance in this population. Hippocampal synaptic alterations occur before clinical symptoms in APOE ε4/ε4 carriers.
我们使用突触囊泡2A正电子发射断层扫描(PET)研究了海马突触密度,以及其与健康载脂蛋白E(APOE)ε4携带者中β淀粉样蛋白(Aβ)和认知表现的关联。
通过使用半卵圆中心作为参考区域,对46名个体(APOE ε4/ε4 n = 14;APOE ε3/ε4 n = 16;APOE ε3/ε3 n = 16)进行[C]UCB-J-PET标准化摄取值比率(SUVRs)评估,以评估突触密度。采用方差分析(ANOVA)和线性模型分析海马[C]UCB-J SUVRs的差异。采用Spearman相关性分析[C]UCB-J SUVR、Aβ、海马体积和认知变量之间的关联。
APOE组之间海马突触密度存在差异(P = 0.016):与APOE ε3/ε3相比,APOE ε4/ε4携带者的[C]UCB-J SUVRs较低(p = 0.013)。海马突触密度与阿尔茨海默病注册协会(CERAD)总分(rho = -0.052,p = 0.74)、阿尔茨海默病预防计划临床前认知综合评分(APCC)(rho = 0.17,p = 0.28)或[C]PiB摄取量(rho = -0.10,p = 0.50)均无相关性。
海马突触丧失在AD连续过程中出现较早,且在认知未受损的高危个体中可在体内测量到。
使用[C]UCB-J正电子发射断层扫描在健康老年人中对突触密度进行了体内研究。与APOE ε3/ε3相比,载脂蛋白E(APOE)ε4/ε4携带者的海马突触密度较低。该人群中突触密度与认知表现无关。APOE ε4/ε4携带者在临床症状出现之前就发生了海马突触改变。